

# PRECEPTORSHIP PROGRAMME

## Prostate Cancer

Multidisciplinary management,  
standards of care, therapeutic targets  
and future perspectives

**ESMO VIRTUAL  
PRECEPTORSHIP**

**15 OCTOBER 2020**

**Co-Chairs**

Karim Fizazi, France

Silke Gillessen, Switzerland

# ESMO VIRTUAL PRECEPTORSHIP PROGRAMME PROSTATE CANCER

Multidisciplinary management, standards of care,  
therapeutic targets and future perspectives

15 October 2020

**CO-CHAIRS:** Karim Fizazi, France  
Silke Gillissen, Switzerland

**SPEAKERS:** Gerhardt Attard, United Kingdom  
Eva Comperat, France  
Theo M. de Reijke, Netherlands  
Valérie Fonteyne, Belgium  
Anne-Laure Giraudet, France

## LEARNING OBJECTIVES

- To learn about fundamentals of epidemiology, natural history and diagnosis as contributing factors to heterogeneity in prostate cancer
- To understand essentials in the assessment and multidisciplinary treatment of prostate cancer
- To learn about advances in treatment and novel targets in prostate cancer

## ACCREDITATION

The programme of this event has been accredited with **5 ESMO-MORA category 1 points**.  
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to [esmo.org](http://esmo.org).

## ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4  
6900 Lugano  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



**All timings are to be considered CEST (Central European Summer Time)**

**Thursday, 15 October 2020**

|                           |  |   |
|---------------------------|--|---|
| <b>09:00-09:05</b><br>05' | <b>Opening and welcome</b>   |   |
| 05'                       | Welcome from ESMO - Objectives and scientific introduction   | Karim Fizazi, FR  |
| <b>09:05-10:15</b><br>70' | <b>SESSION 1</b><br><b>Screening, diagnosis, staging and localized prostate cancer</b>   | <b>Moderators: Silke Gillessen, CH and Karim Fizazi, FR</b> |
| 15'                       | PSA screening, diagnosis and staging classification  | Theo M. de Reijke, NL                                       |
| 15'                       | Pathology and molecular classification for the clinician   | Eva Comperat, FR  |
| 20'                       | Treatment of localized prostate cancer according to risk category  | Theo M. de Reijke, NL                                       |
| 10'                       | Discussion   | Faculty and all   |
| 10'                       | Case presentation localised prostate cancer  | Participant   |
| <b>10:15-10:30</b>        | <b>Break</b>   |   |
| <b>10:30-12:00</b><br>90' | <b>SESSION 2</b><br><b>Systemic treatment and metastatic disease</b>   | <b>Moderators: Silke Gillessen, CH and Karim Fizazi, FR</b> |
| 20'                       | ADT and other hormonal treatments, mechanisms of action, main efficacy results and toxicities  | Silke Gillessen, CH   |
| 15'                       | Bone health agents, mechanism of action, efficacy and toxicities   | Karim Fizazi, FR  |
| 15'                       | Chemotherapy (taxanes and platins) and Radium-223, mechanism of action, main efficacy results in Castration-Resistant Prostate Cancer (CRPC) and toxicities                                    | Gerhardt Attard, UK   |
| 20'                       | Immunotherapy and other new treatments (including DNA repair)  | Karim Fizazi, FR  |
| 10'                       | Discussion   | Faculty and all   |
| 10'                       | Case presentation advanced prostate cancer   | Participant   |
| <b>12:00-14:00</b>        | <b>Break</b>   |   |
| <b>14:00-15:30</b><br>90' | <b>SESSION 3</b><br><b>Advanced prostate cancer</b>  | <b>Moderators: Silke Gillessen, CH and Karim Fizazi, FR</b> |
| 20'                       | Rising PSA and detectable PSA after radical local treatment: Prognosis, indications for salvage local treatments, adjuvant vs salvage treatments, use of early vs deferred systemic treatments | Valérie Fonteyne, BE  |
| 20'                       | Metastatic Castration-Sensitive Prostate Cancer (mCSPC)  | Silke Gillessen, CH   |
| 15'                       | MO CRPC: Prognosis and treatments  | Karim Fizazi, FR  |
| 15'                       | Predictive and prognostic Biomarkers   | Gerhardt Attard, UK   |
| 10'                       | Discussion   | Faculty and all   |
| 10'                       | Case presentation advanced prostate cancer   | Participant   |
| <b>15:30-15:45</b>        | <b>Break</b>   |   |

|                    |   |   |
|--------------------|---|---|
| 15:45-17:00<br>75' | <b>SESSION 4</b><br><b>Metastatic disease</b> | <b>Moderators: Silke Gillessen, CH and Karim Fizazi, FR</b> |
| 15'                | Oligo-metastatic treatment: what treatment?   | Valérie Fonteyne, BE  |
| 20'                | Metastatic CRPC: Current treatment            | Silke Gillessen, CH   |
| 20'                | PSMA in diagnostic and therapy                | Anne-Laure Giraudet, FR                                     |
| 10'                | Discussion                                    | Faculty and all   |
| 10'                | Case presentation metastatic prostate cancer  | Participant   |
| 17:00-17:05<br>05' | <b>Conclusion and farewell</b>                | <b>Karim Fizazi, FR</b>                                     |

**Note:** Each 10 minutes slot for clinical case discussion includes 5' case presentation and 5' Q&A/panel discussion